Frontier Capital Management’s TherapeuticsMD TXMD Stock Holding History

Frontier Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-128,230	Closed	-$15.5M	–	291
2019 Q4	$15.5M	Buy	128,230 +13,250	+12%	+$1.91M	0.11%	198
2019 Q3	$20.9M	Sell	114,980 -19,666	-15%	-$2.77M	0.16%	165
2019 Q2	$17.5M	Buy	134,646 +17,504	+15%	+$3.14M	0.13%	181
2019 Q1	$28.5M	Buy	117,142 +87,219	+291%	+$23.1M	0.2%	158
2018 Q4	$5.7M	Buy	+29,923	New	+$7.3M	0.05%	259

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frontier Capital Management's TXMD Position: Q1 2020 in Review

Frontier Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 128,230 shares — an estimated $15.5M sold.

Frontier Capital Management first reported a position in TXMD in Q4 2018 and held it in 5 quarters. The position peaked at $28.5M in Q1 2019. 142 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Frontier Capital Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Frontier Capital Management sold 128,230 TherapeuticsMD shares in Q1 2020, an estimated $15.5M.
Frontier Capital Management first reported a position in TherapeuticsMD in Q4 2018 and held it in 5 quarters.
Frontier Capital Management's TherapeuticsMD position peaked at $28.5M in Q1 2019.
142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Frontier Capital Management's 13F filing for Q1 2020, filed 16 Apr 2020.